SGMO Sangamo Therapeutics Inc.

11.35
+0.3  (+3%)
Previous Close 11.05
Open 11.13
Price To Book 2.95
Market Cap 1,312,912,124
Shares 115,675,077
Volume 1,296,863
Short Ratio
Av. Daily Volume 1,879,911

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 follow-up data due 4Q 2019.
SB-525
Hemophilia A
Phase 1/2 further data due 4Q 2019.
ST-400
beta-thalassemia
Phase 1/2 longer-term safety and biochemical data due in 2019.
SB-318
MPS Type 1
Phase 1/2 data due 2019.
SB-FIX
Hemophilia B
Phase 1/2 updates during 2019.
SB-913 - CHAMPIONS
MPS Type 2
Phase 1/2 trial to be initiated 2019.
ST-920
Fabry disease

Latest News

  1. Does Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Salary Reflect Performance?
  2. Edited Transcript of SGMO earnings conference call or presentation 7-Aug-19 9:00pm GMT
  3. Sangamo Biosciences Inc (SGMO) Q2 2019 Earnings Call Transcript
  4. What You'll Want to Know About Sangamo Therapeutics' Q2 Results
  5. Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
  6. Sangamo Therapeutics Reports Second Quarter 2019 Financial Results
  7. Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
  8. BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss
  9. Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
  10. Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast
  11. Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases
  12. Shake-Up in Big Weed
  13. Here's Why Sangamo Therapeutics Jumped 23% in June
  14. Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
  15. Sangamo Therapeutics Rises on Positive Clinical Trial Results
  16. A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019
  17. BioMarin (BMRN) to File for Hemophilia A Candidate in Q4
  18. What Happened in the Stock Market Today
  19. Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals